Trial Profile

Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CD40 ligand MUC1 loaded dendritic cell vaccine (Primary)
Indications Adenocarcinoma; Breast cancer; Colon cancer; Lung cancer; Ovarian cancer; Prostate cancer
Focus Adverse reactions; First in man

Most Recent Events

05 Jun 2018 Results (n=18) assessing dose-escalation cohort in a phase 1 study of Ad-sig-hMUC-1/ecdCD40L vector vaccine, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
05 Jun 2018 New source identified and integrated (ClinicalTrials.gov NCT02140996).
18 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com